Skip to content

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cost-Effectiveness of Perioperative Enfortumab Vedotin and Pembrolizumab for Bladder Cancer

This economic evaluation assesses the health economic value, for a US Medicare payer, of adopting perioperative enfortumab vedotin plus pembrolizumab for treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer.

Z. Su, Tyler S. Garman, Carlos A. Rivera López et al. · 0 citations
Open access Sep 2026

Distribution of industry-sponsored research payments to US physician principal investigators

Background The Open Payments program (OPP) was launched in 2013 following the passage of the Physician Payments Sunshine Act (PPSA) to promote transparency of physician-industry financial relationships. Extensive research has scrutinized general (non-research) payments from industry to physicians. However, industry-spo...

Z. Su, Z. Hammadeh, Logan B. Galansky et al. · 0 citations
Open access Sep 2026

Is a Few Too Many? Alcohol Consumption and Prostate Cancer Upgrading During Active Surveillance.

BACKGROUND The association between alcohol consumption and prostate cancer (PCa) outcomes remains mixed, with particularly limited data on the association between alcohol consumption and risk of upgrading among men undergoing active surveillance (AS). METHODS We analyzed men with Grade Group (GG) 1 PCa managed in a p...

Jack A. Campbell, Michelle I. Higgins, Z. Su et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.